• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医院获得性肺炎:经验教训。

Nosocomial pneumonia: lessons learned.

机构信息

Pulmonary and Critical Care Medicine, Winthrop-University Hospital, Mineola, NY 11501, USA.

出版信息

Crit Care Clin. 2013 Jul;29(3):521-46. doi: 10.1016/j.ccc.2013.03.007. Epub 2013 Apr 30.

DOI:10.1016/j.ccc.2013.03.007
PMID:23830652
Abstract

Nosocomial pneumonia remains a significant cause of hospital-acquired infection, imposing substantial economic burden on the health care system worldwide. Various preventive strategies have been increasingly used to prevent the development of pneumonia. It is now recognized that patients with health care-associated pneumonia are a heterogeneous population and that not all are at risk for infection with nosocomial pneumonia pathogens, with some being infected with the same organisms as in community-acquired pneumonia. This review discusses the risk factors for nosocomial pneumonia, controversies in its diagnosis, and approaches to the treatment and prevention of nosocomial and health care-associated pneumonia.

摘要

医院获得性肺炎仍然是医院感染的重要原因,给全球的医疗保健系统带来了巨大的经济负担。目前已经越来越多地使用各种预防策略来预防肺炎的发生。现在已经认识到,与医疗保健相关的肺炎患者是一个异质人群,并非所有人都存在感染医院获得性肺炎病原体的风险,其中一些人感染的病原体与社区获得性肺炎相同。本文讨论了医院获得性肺炎的危险因素、其诊断中的争议,以及医院获得性肺炎和与医疗保健相关肺炎的治疗和预防方法。

相似文献

1
Nosocomial pneumonia: lessons learned.医院获得性肺炎:经验教训。
Crit Care Clin. 2013 Jul;29(3):521-46. doi: 10.1016/j.ccc.2013.03.007. Epub 2013 Apr 30.
2
Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.诗里拉吉医院成人医院获得性肺炎和呼吸机相关性肺炎:病因、临床结局及抗菌药物耐药性的影响
J Med Assoc Thai. 2010 Jan;93 Suppl 1:S126-38.
3
The role of the intensive care unit environment in the pathogenesis and prevention of ventilator-associated pneumonia.重症监护病房环境在呼吸机相关性肺炎发病机制及预防中的作用
Respir Care. 2005 Jun;50(6):813-36; discussion 836-8.
4
Current concepts in the prevention and treatment of ventilator-associated pneumonia.呼吸机相关性肺炎的预防与治疗的当前概念
J Pharm Pract. 2010 Feb;23(1):25-32. doi: 10.1177/0897190009356553.
5
Ventilator-associated pneumonia.呼吸机相关性肺炎。
Respirology. 2009 Nov;14 Suppl 2:S51-8. doi: 10.1111/j.1440-1843.2009.01577.x.
6
Nosocomial pneumonia: de-escalation is what matters.医院获得性肺炎:降阶梯治疗才是关键。
Lancet Infect Dis. 2011 Mar;11(3):155-7. doi: 10.1016/S1473-3099(11)70003-2. Epub 2011 Jan 20.
7
Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units.欧洲重症监护病房中需要机械通气的患者医院获得性肺炎诊断的实践范围
Crit Care Med. 2009 Aug;37(8):2360-8. doi: 10.1097/CCM.0b013e3181a037ac.
8
Nosocomial pneumonia: state of the science.医院获得性肺炎:科学现状
Am J Infect Control. 2006 Mar;34(2):84-93. doi: 10.1016/j.ajic.2005.07.003.
9
The research agenda in VAP/HAP: next steps.呼吸机相关性肺炎/医院获得性肺炎的研究议程:后续步骤
Intensive Care Med. 2017 Sep;43(9):1389-1391. doi: 10.1007/s00134-017-4695-2. Epub 2017 Feb 14.
10
Treatment options for nosocomial pneumonia due to MRSA.耐甲氧西林金黄色葡萄球菌引起的医院获得性肺炎的治疗选择。
J Infect. 2009 Sep;59 Suppl 1:S25-31. doi: 10.1016/S0163-4453(09)60005-0.

引用本文的文献

1
Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020-2022).氨曲南-阿维巴坦及其他β-内酰胺酶抑制剂组合对从美国医疗中心因肺炎住院患者中分离出的革兰氏阴性菌的活性(2020 - 2022年)
BMC Pulm Med. 2025 Jan 24;25(1):38. doi: 10.1186/s12890-025-03500-8.
2
Evaluations of FDA-approved Drugs Targeting 3CLP of SARS-CoV-2 Employing a Repurposing Strategy.采用重新定位策略评估针对 SARS-CoV-2 3CLP 的 FDA 批准药物。
Comb Chem High Throughput Screen. 2024;27(19):2805-2815. doi: 10.2174/1386207325666220816125639.
3
Clinical application of metagenomic next-generation sequencing technology in the diagnosis and treatment of pulmonary infection pathogens: A prospective single-center study of 138 patients.
宏基因组下一代测序技术在肺部感染病原体诊断和治疗中的临床应用:一项前瞻性单中心 138 例患者研究。
J Clin Lab Anal. 2022 Jul;36(7):e24498. doi: 10.1002/jcla.24498. Epub 2022 May 27.
4
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020.2020 年,在欧洲医疗机构中住院治疗肺炎的患者中分离的铜绿假单胞菌对新型β-内酰胺/β-内酰胺酶抑制剂复方制剂的比较活性。
Eur J Clin Microbiol Infect Dis. 2022 Feb;41(2):319-324. doi: 10.1007/s10096-021-04363-7. Epub 2021 Oct 16.
5
Real-World Use of Generic Meropenem: Results of an Observational Study.美罗培南仿制药的真实世界使用情况:一项观察性研究的结果
Antibiotics (Basel). 2021 Jan 11;10(1):62. doi: 10.3390/antibiotics10010062.
6
Disturbance in the oropharyngeal microbiota in relation to antibiotic and proton pump inhibitor medication and length of hospital stay.口咽微生物群与抗生素和质子泵抑制剂药物及住院时间的关系。
APMIS. 2021 Jan;129(1):14-22. doi: 10.1111/apm.13087. Epub 2020 Oct 17.
7
Tigecycline Therapy for Multi-drug-Resistant Sepsis Associated with Multi-organ Failure in an Infant with Persistent Arterial Duct. Case Report.替加环素治疗持续性动脉导管未闭婴儿多药耐药性败血症合并多器官功能衰竭。病例报告。
SN Compr Clin Med. 2020;2(8):1248-1250. doi: 10.1007/s42399-020-00395-w. Epub 2020 Jul 13.
8
[Update on respiratory infections in the emergency department].[急诊科呼吸道感染的最新情况]
Medicine (Madr). 2019 Oct;12(88):5170-5179. doi: 10.1016/j.med.2019.10.013. Epub 2019 Nov 7.
9
Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe.头孢洛扎他唑巴坦和对照药物对来自美国和欧洲的流感嗜血杆菌临床分离株的抗菌活性。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.00211-20.
10
Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia.淋巴细胞减少作为重症监护病房获得性肺炎患者死亡率的预测指标
J Clin Med. 2019 Jun 13;8(6):843. doi: 10.3390/jcm8060843.